These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24735395)

  • 21. Retigabine holds KV7 channels open and stabilizes the resting potential.
    Corbin-Leftwich A; Mossadeq SM; Ha J; Ruchala I; Le AH; Villalba-Galea CA
    J Gen Physiol; 2016 Mar; 147(3):229-41. PubMed ID: 26880756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of Kv7 Potassium Channels Inhibits Intracellular Ca
    Ambrosino P; Soldovieri MV; Di Zazzo E; Paventi G; Iannotti FA; Mosca I; Miceli F; Franco C; Canzoniero LMT; Taglialatela M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
    Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Retigabine - a new antiepileptic drug with a different mechanism of action].
    Zwierzyńska E; Pietrzak B
    Postepy Hig Med Dosw (Online); 2013 Sep; 67():973-81. PubMed ID: 24088541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
    Zhang F; Liu S; Jin L; Tang L; Zhao X; Yang T; Wang Y; Huo B; Liu R; Li H
    Pharmacology; 2020; 105(7-8):471-476. PubMed ID: 32062659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats.
    Nassoiy SP; Byron KL; Majetschak M
    J Biomed Sci; 2017 Jan; 24(1):8. PubMed ID: 28095830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain.
    Cai J; Fang D; Liu XD; Li S; Ren J; Xing GG
    Oncol Rep; 2015 Mar; 33(3):1540-50. PubMed ID: 25592230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
    Jensen MM; Lange SC; Thomsen MS; Hansen HH; Mikkelsen JD
    Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):339-42. PubMed ID: 21599837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.
    Dost R; Rundfeldt C
    Epilepsy Res; 2000 Jan; 38(1):53-66. PubMed ID: 10604606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
    Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
    Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
    Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
    PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retigabine: the newer potential antiepileptic drug.
    Czuczwar P; Wojtak A; Cioczek-Czuczwar A; Parada-Turska J; Maciejewski R; Czuczwar SJ
    Pharmacol Rep; 2010; 62(2):211-9. PubMed ID: 20508276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels.
    Yau MC; Kim RY; Wang CK; Li J; Ammar T; Yang RY; Pless SA; Kurata HT
    J Gen Physiol; 2018 Oct; 150(10):1421-1431. PubMed ID: 30166314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
    Punke MA; Friederich P
    Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining endocannabinoids with retigabine for enhanced M-channel effect and improved KV7 subtype selectivity.
    Larsson JE; Karlsson U; Wu X; Liin SI
    J Gen Physiol; 2020 Aug; 152(8):. PubMed ID: 32365171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine.
    Vicente-Baz J; Lopez-Garcia JA; Rivera-Arconada I
    Neuropharmacology; 2016 Oct; 109():131-138. PubMed ID: 27263036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
    Sander SE; Lemm C; Lange N; Hamann M; Richter A
    Neuropharmacology; 2012 Feb; 62(2):1052-61. PubMed ID: 22079161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible involvement of nitric oxide modulatory mechanism in the protective effect of retigabine against spinal nerve ligation-induced neuropathic pain.
    Pottabathini R; Kumar A; Bhatnagar A; Garg S
    Cell Mol Neurobiol; 2015 Jan; 35(1):137-46. PubMed ID: 25182225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons.
    Ghezzi F; Monni L; Nistri A
    J Physiol; 2018 Jul; 596(13):2611-2629. PubMed ID: 29736957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.